InTrack Investment Management Inc Lowers Position in Eli Lilly and Company $LLY

InTrack Investment Management Inc cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,720 shares of the company’s stock after selling 230 shares during the period. Eli Lilly and Company comprises about 1.4% of InTrack Investment Management Inc’s investment portfolio, making the stock its 20th biggest position. InTrack Investment Management Inc’s holdings in Eli Lilly and Company were worth $2,120,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department lifted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Guggenheim boosted their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Leerink Partners restated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Finally, Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $943.00.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE LLY opened at $845.55 on Thursday. The business’s 50 day moving average is $738.69 and its two-hundred day moving average is $766.57. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The stock has a market capitalization of $800.28 billion, a P/E ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 earnings per share. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.